Latest Stories
Cannabis Law Special Section 2024
This year's special section explores how the cannabis market could affect the legalization of psychedelics in New Jersey; how the rescheduling of cannabis could affect the financial sector and federal trademarks; among other topics.
'Politics for Profit': Menendez Found Guilty on All Counts in Bribery Trial
The trial centered on the origin of valuables, including gold bars and cash, discovered by law enforcement officials around the New Jersey home of the senator and his wife.
Legal Cannabis in New Jersey—Core Developments and What to Expect Next
"Some of the issues identified are unique to New Jersey's approach to creating this new marketplace and others are endemic to the bipolar nature of cannabis in the country," writes Charles Gormally.
How Will Cannabis Rescheduling Affect Federal Trademarks?
"There are a number of different strategies that cannabis companies can employ to obtain federal trademark registrations," writes Matthew G. Miller of Lerner David.
Navigating Local Hurdles: Challenges Facing Cannabis Applicants in New Jersey
"Navigating New Jersey's evolving cannabis regulations poses substantial challenges for businesses, primarily due to municipalities' broad authority under CREAMMA," write Mandelbaum Barrett's Joshua S. Bauchner and Natalie C. Diaz.
Crackdown on Synthetic Cannabinoids: How New Jersey Is Trying to Curb Hemp-Derived THC Products
"Seventeen states have banned intoxicating hemp products, and seven states have implemented stringent restrictions," write Stark & Stark's Gene Markin and Dillon Collins.
Banking on Change: How Rescheduling Cannabis Could Impact the Financial Sector
"Rescheduling marijuana to Schedule III could reduce some criminal penalties and allow marijuana businesses to take federal tax deductions," write Fox Rothschild's Nikolas S. Komyati and Fruqan Mouzon.
Joint Effort: How Cannabis Legalization Is Shaping New Jersey's Psychedelics Legislation
"The legislative evolution from cannabis to psilocybin in New Jersey reflects a growing recognition of the need for evidence-based drug policy reform," write Guillermo Artiles and Ryan M. Magee of McCarter & English.
Menendez Jury Adjourns Second Day of Deliberations With No Verdict
The panel had multiple questions on Monday, including if unanimity was required to acquit a defendant "on a single count."
Saul Ewing Attorneys to Defend AI Pharma-Tech Company in Securities Class Action
Saul Ewing's Sarah A. Sullivan and Alexander Lee Callo in Newark have recently entered appearances on behalf of an artificial intelligence-driven pharma-tech company sued in a pending securities class action.Trending Stories
- 1States Accuse Trump of Thwarting Court's Funding Restoration Order
- 2Microsoft Becomes Latest Tech Company to Face Claims of Stealing Marketing Commissions From Influencers
- 3Coral Gables Attorney Busted for Stalking Lawyer
- 4Trump's DOJ Delays Releasing Jan. 6 FBI Agents List Under Consent Order
- 5Securities Report Says That 2024 Settlements Passed a Total of $5.2B
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
